All In Biotech

NDA 209637 · Novo

Ozempic

Semaglutide · Subcutaneous

Novel

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 5, 2017

Approved uses

4

Original approval plus efficacy supplements

Registered trials

626

187 Phase 3, 161 recruiting

FAERS reports

70,721

35,100 serious, 1,193 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid...

What it is approved for

From the label in effect Jul 30, 2026.

OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) • to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease. ( 1 )

Mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • OZEMPIC · SEMAGLUTIDE 8MG/3ML (2.68MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • OZEMPIC · SEMAGLUTIDE 2MG/1.5ML (1.34MG/ML) · SOLUTION, SUBCUTANEOUS · Discontinued
  • OZEMPIC · SEMAGLUTIDE 0.5MG/0.5ML (0.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • OZEMPIC · SEMAGLUTIDE 2MG/3ML (0.68MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • OZEMPIC · SEMAGLUTIDE 4MG/3ML (1.34MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • OZEMPIC · SEMAGLUTIDE 1MG/0.5ML (1MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • OZEMPIC · SEMAGLUTIDE 0.25MG/0.5ML (0.25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.

All 626 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea10,175
  • off label use7,482
  • vomiting6,675
  • diarrhoea6,326
  • decreased appetite4,685
  • constipation4,636
  • weight decreased4,425
  • impaired gastric emptying4,024
  • product use in unapproved indication3,555
  • blood glucose increased3,101
  • wrong technique in product usage process3,008
  • abdominal pain upper2,957

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20143
20157
201612
201713
20181,140
20191,589
20203,032
20213,730
20225,301
20238,478
202412,875
202518,612
202615,927

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ozempic (Semaglutide)

2024 spending

$13.0B

Beneficiaries

1,952,637

10,417,182 claims

Per beneficiary

$6,642

$306.48 per unit

View as table
YearSpending
2020$1,455,812,267
2021$2,621,694,348
2022$4,628,160,643
2023$9,194,048,435
2024$12,970,296,347

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 784 on PubMed

Sponsor: Novo

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.